| Missing Links? Citation Matrix | Graphs | Glossary HistCite Guide About |
|
MELLIN GW, 1962, NEW ENGL J MED, V267, P1184 MELLIN GW, 1962, NEW ENGL J MED, V267, P1238 LENZ W, 1961, DEUT MED WOCHENSCHR, V86, P2555 LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232 KUNZ W, 1956, ARZNEIMITTEL-FORSCH, V6, P426 SHESKIN J, 1965, LEPROSY REV, V36, P183 WIEDEMANN HR, 1961, MED WELT, V37, P1863 BECKMANN R, 1962, ARZNEIMITTEL-FORSCH, V12, P1095 |
Nodes: 2685,
Authors: 6203,
Journals: 662,
Outer References: 16023,
Words: 3995
Collection span: 1956 - 2004
View: Overview. Sorted by journal name.
Page 7: 1 2 3 4 5 6 7 8 9
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
|---|---|---|---|---|---|
| 1801 | 6 | 27 | 468 1968 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 161(2):348-& BAKAY B; NYHAN WL BINDING THALIDOMIDE BY MACROMOLECULES IN FETAL AND MATERNAL RAT | 11 | 16 |
| 1802 | 1 | 14 | 504 1970 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 171(1):109-& BAKAY B; NYHAN WL EFFECTS OF THALIDOMIDE AND CHLORCYCLIZINE ON BIOSYNTHESIS OF NUCLEIC ACIDS AND PROTEINS IN FETAL AND MATERNAL TISSUES OF RAT | 4 | 5 |
| 1803 | 6 | 12 | 505 1970 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 173(2):265-& SCHUMACHER HJ; WILSON JG; TERAPANE JF; ROSEDALE SL THALIDOMIDE - DISPOSITION IN RHESUS MONKEY AND STUDIES OF ITS HYDROLYSIS IN TISSUES OF THIS AND OTHER SPECIES | 18 | 20 |
| 1804 | 4 | 19 | 650 1977 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 203(1):240-251 FREDERICKSON RCA; SLATER IH; DUSENBERRY WE; HEWES CR; JONES GT; MOORE RA COMPARISON OF THALIDOMIDE AND PENTOBARBITAL - NEW METHODS FOR IDENTIFYING NOVEL HYPNOTIC DRUGS | 0 | 9 |
| 1805 | 23 | 76 | 1280 1996 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 277(3):1649-1658 Arlen RR; Wells PG Inhibition of thalidomide teratogenicity by acetylsalicylic acid: Evidence for prostaglandin H synthase-catalyzed bioactivation of thalidomide to a teratogenic reactive intermediate | 9 | 15 |
| 1806 | 8 | 27 | 1971 2001 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 298(3):1221-1226 Drenth JPH; Vonk AG; Simon A; Powell R; Van der Meer JWM Limited efficacy of thalidomide in the treatment of febrile attacks of the hyper-IgD and periodic fever syndrome: A randomized, double-blind, placebo-controlled trial | 1 | 7 |
| 1807 | 15 | 40 | 2243 2002 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 300(3):768-776 Hansen JM; Harris KK; Philbert MA; Harris C Thalidomide modulates nuclear redox status and preferentially depletes glutathione in rabbit limb versus rat limb | 2 | 5 |
| 1808 | 9 | 39 | 2496 2003 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 305(3):1222-1232 Schafer PH; Gandhi AK; Loveland MA; Chen RS; Man HW; Schnetkamp PPM; Wolbring G; Govinda S; Corral LG; Payvandi F; Muller GW; Stirling DI Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs | 3 | 4 |
| 1809 | 20 | 27 | 2647 2004 JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 310(2):571-577 Lu J; Helsby N; Palmer BD; Tingle M; Baguley BC; Kestell P; Ching LM Metabolism of thalidomide in liver microsomes of mice, rabbits, and humans | 0 | 0 |
| 1810 | 1 | 7 | 9 1960 JOURNAL OF PHARMACY AND PHARMACOLOGY 12:T153-T158 MARTINDALE K; SOMERS GF; WILSON CWM THE EFFECT OF THALIDOMIDE IN EXPERIMENTAL GASTRIC ULCERS | 0 | 15 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1811 | 0 | 1 | 44 1961 JOURNAL OF PHARMACY AND PHARMACOLOGY 13:T117-& GREEN JN; BENSON BC SPECTROPHOTOMETRIC DETERMINATION OF THALIDOMIDE IN BODY FLUIDS | 11 | 12 |
| 1812 | 8 | 13 | 386 1966 JOURNAL OF PHARMACY AND PHARMACOLOGY 18(1):46-& NICHOLLS PJ A NOTE ON ABSORPTION AND EXCRETION OF 14C-LABELLED THALIDOMIDE IN PREGNANT MICE | 7 | 7 |
| 1813 | 17 | 29 | 436 1967 JOURNAL OF PHARMACY AND PHARMACOLOGY 19(9):603-& HAGUE DE; FABRO S; SMITH RL FATE OF [14C]THALIDOMIDE IN PREGNANT HAMSTER | 6 | 8 |
| 1814 | 21 | 27 | 1451 1998 JOURNAL OF PHARMACY AND PHARMACOLOGY 50(12):1409-1416 Eriksson T; Bjorkman S; Roth B; Bjork H; Hoglund P Hydroxylated metabolites of Thalidomide: Formation in-vitro and in-vivo in man | 23 | 24 |
| 1815 | 28 | 36 | 1750 2000 JOURNAL OF PHARMACY AND PHARMACOLOGY 52(7):807-817 Eriksson T; Bjorkman S; Roth B; Hoglund P Intravenous formulations of the enantiomers of thalidomide: Pharmacokinetic and initial pharmacodynamic characterization in man | 10 | 17 |
| 1816 | 13 | 23 | 2497 2003 JOURNAL OF PHARMACY AND PHARMACOLOGY 55(12):1701-1706 Eriksson T; Hoglund P; Turesson I; Waage A; Don BR; Vu J; Scheffler M; Kaysen GA Pharmacokinetics of thalidomide in patients with impaired renal function and while on and off dialysis | 3 | 3 |
| 1817 | 0 | 0 | 756 1981 JOURNAL OF POST KEYNESIAN ECONOMICS 3(3):459-462 WEINTRAUB S THE CARTER ECONOMIC COUNCILS THALIDOMIDE TIP | 0 | 0 |
| 1818 | 0 | 0 | 2244 2002 JOURNAL OF PSYCHOPHYSIOLOGY 16(4):249-250 Stoeckel MC; Pollock B; Stoerig P; Witte OW; Schnitzler A; Seitz RJ Mislocalizations across toes as evidence for sensorimotor plasticity in thalidomide embryopathy | 0 | 0 |
| 1819 | 3 | 19 | 286 1964 JOURNAL OF REPRODUCTION AND FERTILITY 8(1):59-& HAY MF EFFECTS OF THALIDOMIDE ON PREGNANCY IN RABBIT | 9 | 30 |
| 1820 | 6 | 14 | 387 1966 JOURNAL OF REPRODUCTION AND FERTILITY 11(1):157-& FRITZ H FAILURE OF THALIDOMIDE METABOLITES TO PRODUCE MALFORMATIONS IN RABBIT EMBRYO | 8 | 11 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1821 | 15 | 27 | 997 1989 JOURNAL OF RHEUMATOLOGY 16(2):158-163 GUTIERREZRODRIGUEZ O; STARUSTABACAL P; GUTIERREZMONTES O TREATMENT OF REFRACTORY RHEUMATOID-ARTHRITIS - THE THALIDOMIDE EXPERIENCE | 55 | 72 |
| 1822 | 11 | 33 | 1452 1998 JOURNAL OF RHEUMATOLOGY 25(5):964-969 Oliver SJ; Cheng TP; Banquerigo ML; Brahn E The effect of thalidomide and 2 analogs on collagen induced arthritis | 15 | 31 |
| 1823 | 11 | 15 | 1571 1999 JOURNAL OF RHEUMATOLOGY 26(11):2344-2347 Keesal N; Wasserman MJ; Bookman A; Lapp V; Weber DA; Keystone EC Thalidomide in the treatment of refractory rheumatoid arthritis | 14 | 17 |
| 1824 | 20 | 27 | 1751 2000 JOURNAL OF RHEUMATOLOGY 27(6):1429-1433 Ordi-Ros J; Cortes F; Cucurull E; Mauri M; Bujan S; Vilardell M Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy | 15 | 28 |
| 1825 | 19 | 32 | 2498 2003 JOURNAL OF RHEUMATOLOGY 30(12):2627-2631 Wei JCC; Chan TW; Lin HS; Huang F; Chou CT Thalidomide for severe refractory ankylosing spondylitis: A 6-month open-label trial | 0 | 1 |
| 1826 | 10 | 20 | 1281 1996 JOURNAL OF SURGICAL RESEARCH 63(1):143-146 Schmidt H; Rush B; Simonian G; Murphy T; Hsieh J; Condon M Thalidomide inhibits TNF response and increases survival following endotoxin injection in rats | 8 | 17 |
| 1827 | 6 | 23 | 1572 1999 JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN 57(2):92-104 Shimazawa R; Takayama H; Hashimoto Y Development of novel biological response modifiers derived from thalidomide | 0 | 7 |
| 1828 | 0 | 1 | 287 1964 JOURNAL OF TEACHER EDUCATION 15(4):382-385 ATKYNS GC A THALIDOMIDE SCANDAL IN EDUCATION | 0 | 1 |
| 1829 | 26 | 54 | 784 1982 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 7(3):317-323 BARNHILL RL; MCDOUGALL AC THALIDOMIDE - USE AND POSSIBLE MODE OF ACTION IN REACTIONAL LEPROMATOUS LEPROSY AND IN VARIOUS OTHER CONDITIONS | 84 | 111 |
| 1830 | 22 | 39 | 855 1984 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 11(5):814-819 BARNHILL RL; DOLL NJ; MILLIKAN LE; HASTINGS RC STUDIES ON THE ANTI-INFLAMMATORY PROPERTIES OF THALIDOMIDE - EFFECTS ON POLYMORPHONUCLEAR LEUKOCYTES AND MONOCYTES | 42 | 48 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1831 | 10 | 18 | 892 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 12(1):85-90 GRINSPAN D SIGNIFICANT RESPONSE OF ORAL APHTHOSIS TO THALIDOMIDE TREATMENT | 25 | 42 |
| 1832 | 2 | 9 | 893 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 13(2):304-305 MIYACHI Y; NIWA Y THALIDOMIDE AND OXYGEN INTERMEDIATES | 0 | 0 |
| 1833 | 2 | 3 | 894 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 13(2):305-305 BARNHILL RL THALIDOMIDE AND OXYGEN INTERMEDIATES - REPLY | 0 | 0 |
| 1834 | 1 | 2 | 895 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 13(3):509-509 BRODTHAGEN H SIGNIFICANT RESPONSE OF ORAL APHTHOSIS TO THALIDOMIDE TREATMENT | 1 | 1 |
| 1835 | 2 | 3 | 896 1985 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 13(3):509-509 GRINSPAN D SIGNIFICANT RESPONSE OF ORAL APHTHOSIS TO THALIDOMIDE TREATMENT - REPLY | 1 | 1 |
| 1836 | 5 | 10 | 924 1986 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 14(2):282-283 ARONSON IK; WEBER L; WEST D; BUYS C; REDER A; ANTEL J THALIDOMIDE AND LYMPHOCYTE FUNCTION | 6 | 6 |
| 1837 | 2 | 3 | 925 1986 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 14(2):283-283 MILLIKAN LE; HASTINGS RC THALIDOMIDE AND LYMPHOCYTE FUNCTION - REPLY | 0 | 1 |
| 1838 | 19 | 39 | 998 1989 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 20(6):1060-1063 GRINSPAN D; BLANCO GF; AGUERO S TREATMENT OF APHTHAE WITH THALIDOMIDE | 9 | 23 |
| 1839 | 3 | 13 | 1019 1990 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 23(3):523-525 RADEFF B; KUFFER R; SAMSON J RECURRENT APHTHOUS ULCER IN PATIENT INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS - SUCCESSFUL TREATMENT WITH THALIDOMIDE | 18 | 30 |
| 1840 | 3 | 13 | 1020 1990 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 23(5):941-944 RUSTIN MHA; GILKES JJH; ROBINSON TWE PYODERMA-GANGRENOSUM ASSOCIATED WITH BEHCETS-DISEASE - TREATMENT WITH THALIDOMIDE | 14 | 27 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1841 | 4 | 6 | 1103 1993 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 28(2):271-272 GHIGLIOTTI G; REPETTO T; FARRIS A; ROY MT; DEMARCHI R THALIDOMIDE - TREATMENT OF CHOICE FOR APHTHOUS ULCERS IN PATIENTS SEROPOSITIVE FOR HUMAN-IMMUNODEFICIENCY-VIRUS | 31 | 39 |
| 1842 | 17 | 44 | 1205 1995 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 32(5):866-869 CARLESIMO M; GIUSTINI S; ROSSI A; BONACCORSI P; CALVIERI S TREATMENT OF CUTANEOUS AND PULMONARY SARCOIDOSIS WITH THALIDOMIDE | 48 | 84 |
| 1843 | 4 | 18 | 1206 1995 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 33(2):380-382 MANDERS SM; KOSTMAN JR; MENDEZ L; RUSSIN VL THALIDOMIDE-RESISTANT HIV-ASSOCIATED APHTHAE SUCCESSFULLY TREATED WITH GRANULOCYTE-COLONY-STIMULATING FACTOR | 1 | 7 |
| 1844 | 3 | 6 | 1207 1995 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 33(5):837-838 BERGER TG; HOFFMAN C; THIEBERG MD PRURIGO NODULARIS AND PHOTOSENSITIVITY IN AIDS - TREATMENT WITH THALIDOMIDE | 13 | 22 |
| 1845 | 86 | 101 | 1282 1996 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 35(6):969-979 Tseng S; Pak G; Washenik K; Pomeranz MK; Shupack JL Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses | 76 | 114 |
| 1846 | 12 | 14 | 1453 1998 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 38(3):490-491 Hecker MS; Lebwohl MG Recalcitrant pyoderma gangrenosum: Treatment with thalidomide | 14 | 21 |
| 1847 | 7 | 10 | 1454 1998 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 39(2):293-295 Warren KJ; Nopper AJ; Crosby DL Thalidomide for recalcitrant discoid lesions in a patient with systemic lupus erythematosus | 7 | 9 |
| 1848 | 11 | 18 | 1455 1998 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 39(5):835-838 Lee JB; Koblenzer PS Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: A case report | 14 | 29 |
| 1849 | 6 | 6 | 1972 2001 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 45(6):965-966 George SJ; Hsu S Lichen planopilaris treated with thalidomide | 2 | 5 |
| 1850 | 8 | 15 | 2245 2002 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 47(2):S193-S195 Duong DHJ; Moxley RT; Kellman RM; Pincus SH; Gaspari AA Thalidomide therapy for cicatricial pemphigoid | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1851 | 7 | 10 | 2246 2002 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 47(6):967-968 Boyd AS; King LE; Boyd AS Thalidomide-induced remission of lichen planopilaris | 0 | 0 |
| 1852 | 10 | 14 | 2499 2003 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 48(4):548-552 Hall VC; El-Azhary RA; Bouwhuis S; Rajkumar SV Dermatologic side effects of thalidomide in patients with multiple myeloma | 3 | 4 |
| 1853 | 9 | 12 | 2500 2003 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 48(5):S89-S91 Alfadley A; Al Rayes H; Hussein W; Al Dalaan A; Al-Aboud K Thalidomide for treatment of severe generalized discoid lupus lesions in two patients with systemic lupus erythematosus | 0 | 0 |
| 1854 | 27 | 45 | 2648 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 50(2):235-241 Nguyen YT; Dupuy A; Cordoliani F; Vignon-Pennamen MD; Lebbe C; Morel P; Rybojad M Treatment of cutaneous sarcoidosis with thalidomide | 0 | 0 |
| 1855 | 0 | 0 | 2649 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 50(3):P78-P78 Wu JJ; Pang KR; Hsu S; Tyring SK Thalidomide: A review of new indications | 0 | 0 |
| 1856 | 13 | 23 | 2650 2004 JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 51(1):126-131 Sansbury JC; Cocuroccia B; Jorizzo JL; Gubinelli E; Gisondi P; Girolomoni G Treatment of recalcitrant scleromyxedema with thalidomide in 3 patients | 0 | 0 |
| 1857 | 0 | 0 | 1752 2000 JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 35(2):172A-173A Bozkurt B; Chee A; Lee-Jackson D; Deswal A; Zeldis JB; Mann DL Results of an open label dose response study of thalidomide in patients with advanced heart failure and elevated levels of TNF | 0 | 2 |
| 1858 | 0 | 3 | 340 1965 JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 192(2):173-& APGAR V SEARCH FOR BIRTH DATA ON THALIDOMIDE-SENSITIVE PERIOD | 0 | 0 |
| 1859 | 0 | 4 | 388 1966 JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 195(8):695-& MATTHIES F TRIAD OF ANOTIA FACIAL PARALYSIS AND CARDIAC ANOMALY NOT DUE TO THALIDOMIDE | 0 | 3 |
| 1860 | 11 | 52 | 2501 2003 JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION 10(3):252-259 Weeber M; Vos R; Klein H; de Jong-van den Berg LTW; Aronson AR; Molema G Generating hypotheses by discovering implicit associations in the literature: A case report of a search for new potential therapeutic uses for thalidomide. | 0 | 4 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1861 | 0 | 0 | 2247 2002 JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 13:641A-641A Don BR; Vu JT; Eriksson T; Scheffler M; Kaysen GA Thalidomide is rapidly metabolized in hemodialysis patients and has a 3-fold increase in clearance during dialysis. | 0 | 0 |
| 1862 | 0 | 0 | 2248 2002 JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 13:733A-734A Yudis M; Sirota RA; Stein HD; Snipes ER; Gronich JH; Ghantous VE; Collins DM Renal failure (RF) in multiple myeloma (MM) - Possible association with pamidronate and thalidomide. | 0 | 0 |
| 1863 | 0 | 0 | 2502 2003 JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY 14:807A-807A Yaqub MS Acute renal failure in multiple myeloma patient receiving thalidomide and zoledronic acid infusion. | 0 | 0 |
| 1864 | 0 | 0 | 2503 2003 JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION 222(3):273-273 [Anon] Veterinary use of thalidomide forbidden by FDA | 0 | 0 |
| 1865 | 4 | 37 | 525 1971 JOURNAL OF THE CHEMICAL SOCIETY B-PHYSICAL ORGANIC (6):1073-& ALLEN FH; TROTTER J CRYSTAL AND MOLECULAR STRUCTURE OF THALIDOMIDE, N-(ALPHA-GLUTARIMIDO)-PHTHALIMIDE | 5 | 29 |
| 1866 | 4 | 10 | 506 1970 JOURNAL OF THE CHEMICAL SOCIETY D-CHEMICAL COMMUNICATIONS (12):778-& ALLEN FH; TROTTER J CRYSTAL AND MOLECULAR STRUCTURE OF THALIDOMIDE | 1 | 0 |
| 1867 | 11 | 20 | 1147 1994 JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2 (9):2063-2067 REEPMEYER JC; RHODES MO; COX DC; SILVERTON JV CHARACTERIZATION AND CRYSTAL-STRUCTURE OF 2 POLYMORPHIC FORMS OF RACEMIC THALIDOMIDE | 3 | 4 |
| 1868 | 4 | 16 | 2249 2002 JOURNAL OF THE CHINESE CHEMICAL SOCIETY 49(3):383-385 Chang MY; Chang CH; Chen ST; Chang NC A synthesis of thalidomide | 0 | 9 |
| 1869 | 0 | 1 | 2250 2002 JOURNAL OF THE HISTORY OF BIOLOGY 35(2):387-389 Keiner C Dark remedy: The impact of thalidomide and its revival as a vital medicine | 0 | 0 |
| 1870 | 0 | 15 | 624 1976 JOURNAL OF THE INDIAN CHEMICAL SOCIETY 53(10):1049-1052 DE AU; PAL D QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP (QSAR) AND RATIONAL DRUG DESIGN FOR SOME ANTINEOPLASTIC THALIDOMIDE AND GLUTARIMIDE DERIVATIVES | 0 | 10 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1871 | 0 | 0 | 1363 1997 JOURNAL OF THE NATIONAL CANCER INSTITUTE 89(20):1480-1481 Saphir A Jekyll and Hyde: A new license for thalidomide? | 5 | 7 |
| 1872 | 0 | 0 | 2251 2002 JOURNAL OF THE NATIONAL CANCER INSTITUTE 94(17):1270-1272 Friedrich MJ Despite checkered past, thalidomide and its analogues show potential | 0 | 0 |
| 1873 | 0 | 0 | 2651 2004 JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION 11(2):275A-275A Dharia SP; Steinkampf MP; Parker CR; Grubbs CJ; Crockett S The impact of thalidomide on ovarian function. | 0 | 0 |
| 1874 | 9 | 144 | 856 1984 JOURNAL OF THEORETICAL BIOLOGY 110(3):461-486 SHULL GE DIFFERENTIAL INHIBITION OF PROTEIN-SYNTHESIS - A POSSIBLE BIOCHEMICAL-MECHANISM OF THALIDOMIDE TERATOGENESIS | 4 | 6 |
| 1875 | 6 | 10 | 2504 2003 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(3):421-422 Barbui T; Falanga A Thalidomide and thrombosis in multiple myeloma | 1 | 1 |
| 1876 | 8 | 21 | 2505 2003 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(3):445-449 Minnema MC; Fijnheer R; De Groot PG; Lokhorst HM Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment | 2 | 2 |
| 1877 | 8 | 12 | 2506 2003 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 1(12):2691-2692 Arkel YS; Ku DHW; Thurston AL The effect of thalidomide on tissue factor activity in Mono Mac 6 cells and the relationship to tumor necrosis factor (TNF)- alpha-stimulated cells | 0 | 0 |
| 1878 | 6 | 33 | 2652 2004 JOURNAL OF THROMBOSIS AND HAEMOSTASIS 2(2):327-334 Kaushal V; Kaushal GP; Melkaveri SN; Mehta P Thalidomide protects endothelial cells from doxorubicin-induced apoptosis but alters cell morphology | 0 | 0 |
| 1879 | 0 | 0 | 2507 2003 JOURNAL OF UROLOGY 169(4):233-233 Clark PE; Hall MC; Ridenhour KP; Stindt D; Patton SE; Brinkley W; Das S; Torti FM Phase II trial of thalidomide and interferon-alpha in advanced renal cell carcinoma | 0 | 0 |
| 1880 | 0 | 0 | 1456 1998 JOURNAL OF VASCULAR RESEARCH 35:54-54 Baatz H; Tonnessen B; Pleyer U; Hartmann C Antiinflammatory action of thalidomide: Modulation of leukocyte-endothelium interaction | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1881 | 0 | 0 | 1364 1997 JOURNAL OF WOMENS HEALTH 6(6):614-615 White K Thalidomide may be approved after decades-long US ban | 0 | 0 |
| 1882 | 0 | 1 | 706 1979 JOURNALISM QUARTERLY 56(2):404-404 GREY DL SUFFER THE CHILDREN - STORY OF THALIDOMIDE - "SUNDAY-TIMES-OF-LONDON-INSIGHT-TEAM | 0 | 0 |
| 1883 | 0 | 0 | 825 1983 KEMISK TIDSKRIFT 95(12):74-74 LEVERBECK K SECRET TEST REVEALS THE MUTAGENIC EFFECT OF THALIDOMIDE | 0 | 0 |
| 1884 | 0 | 0 | 1208 1995 KIDNEY INTERNATIONAL 47(2):672-672 RIFLKIN IR; MCHUGH SM; BRADLEY JR; THIRU S; EWAN PW; LOCKWOOD CM THALIDOMIDE AS TREATMENT FOR REFRACTORY SYSTEMIC VASCULITIS - POSSIBLE MECHANISM OF ACTION | 0 | 0 |
| 1885 | 0 | 23 | 572 1973 KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE 162(4):546-550 TRIESCHM.W CROCODILE TEARS IN THALIDOMIDE EMBRYOPATHY | 0 | 4 |
| 1886 | 0 | 0 | 526 1971 KLINISCHE WOCHENSCHRIFT 49(18):1044-& KECK EW; DOLOFF D; MARKWORT.P CARDIOVASCULAR FINDINGS IN CHILDREN WITH THALIDOMIDE DYSMELIA SYNDROME | 0 | 0 |
| 1887 | 10 | 27 | 485 1969 LABORATORY ANIMAL CARE 19(5P2):727-& FRATTA ID NICOTINAMIDE DEFICIENCY AND THALIDOMIDE - POTENTIAL TERATOGENIC DISTURBANCES IN LONG-EVANS RATS | 0 | 0 |
| 1888 | 0 | 0 | 45 1961 LANCET 2(721):1358-& MCBRIDE WG THALIDOMIDE AND CONGENITAL ABNORMALITIES | 181 | 432 |
| 1889 | 0 | 0 | 110 1962 LANCET 1(7219):45-& LENZ W THALIDOMIDE AND CONGENITAL ABNORMALITIES | 122 | 254 |
| 1890 | 1 | 3 | 111 1962 LANCET 1(7219):45-& PFEIFFER RA; KOSENOW W THALIDOMIDE AND CONGENITAL ABNORMALITIES - REPLY | 25 | 44 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1891 | 0 | 0 | 112 1962 LANCET 1(7219):46-& HAYMAN DJ THALIDOMIDE AND CONGENITAL ABNORMALITIES - REPLY | 1 | 1 |
| 1892 | 1 | 1 | 113 1962 LANCET 1(7220):100-& BURLEY DM THALIDOMIDE AND CONGENITAL ABNORMALITIES | 8 | 10 |
| 1893 | 0 | 0 | 114 1962 LANCET 1(7222):222-& JONES EE; WILLIAMSON DAJ THALIDOMIDE AND CONGENITAL ABNORMALITIES | 0 | 11 |
| 1894 | 0 | 0 | 115 1962 LANCET 1(7223):271-& LENZ W THALIDOMIDE AND CONGENITAL ABNORMALITIES - REPLY | 22 | 47 |
| 1895 | 0 | 0 | 116 1962 LANCET 1(7223):271-& BURLEY DM THALIDOMIDE AND CONGENITAL ABNORMALITIES | 13 | 19 |
| 1896 | 5 | 6 | 117 1962 LANCET 1(7224):303-& SPEIRS AL THALIDOMIDE AND CONGENITAL ABNORMALITIES | 33 | 76 |
| 1897 | 6 | 8 | 118 1962 LANCET 1(7224):307-& [Anon] THALIDOMIDE AND CONGENITAL MALFORMATIONS | 1 | 0 |
| 1898 | 0 | 0 | 119 1962 LANCET 1(7224):326-& KOHLER HG; FISHER AM; DUNN PM THALIDOMIDE AND CONGENITAL ABNORMALITIES | 7 | 17 |
| 1899 | 0 | 0 | 120 1962 LANCET 1(7226):429-& RUSSELL CS; MCKICHAN MD THALIDOMIDE AND CONGENITAL ABNORMALITIES | 0 | 16 |
| 1900 | 0 | 0 | 121 1962 LANCET 1(7228):542-& OLIVER MY THALIDOMIDE AND CONGENITAL ABNORMALITIES | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1901 | 0 | 0 | 122 1962 LANCET 1(7229):591-& SMITHELLS RW THALIDOMIDE AND CONGENITAL ABNORMALITIES | 7 | 9 |
| 1902 | 0 | 0 | 123 1962 LANCET 1(7231):691-& FERGUSON AW THALIDOMIDE AND CONGENITAL ABNORMALITIES | 11 | 14 |
| 1903 | 0 | 0 | 124 1962 LANCET 1(7231):691-& ROGERSON G THALIDOMIDE AND CONGENITAL ABNORMALITIES - REPLY | 11 | 13 |
| 1904 | 0 | 0 | 125 1962 LANCET 1(7232):750-& WOODYATT PB THALIDOMIDE | 6 | 8 |
| 1905 | 1 | 3 | 126 1962 LANCET 1(7235):912-& SOMERS GF THALIDOMIDE AND CONGENITAL ABNORMALITIES | 79 | 168 |
| 1906 | 0 | 0 | 127 1962 LANCET 1(7239):1128-& PLIESS G THALIDOMIDE AND CONGENITAL ABNORMALITIES | 22 | 37 |
| 1907 | 6 | 18 | 128 1962 LANCET 1(7242):1270-& SMITHELLS RW THALIDOMIDE AND MALFORMATIONS IN LIVERPOOL | 24 | 47 |
| 1908 | 1 | 1 | 129 1962 LANCET 1(7244):1402-& QUIBELL EP THALIDOMIDE-DAMAGED INFANTS | 2 | 2 |
| 1909 | 0 | 0 | 130 1962 LANCET 2(7245):46-& WHATLEY E THALIDOMIDE-DAMAGED BABIES | 1 | 2 |
| 1910 | 0 | 0 | 131 1962 LANCET 2(7246):100-& SPENCER KEV THALIDOMIDE AND CONGENITAL ABNORMALITIES | 18 | 31 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1911 | 0 | 0 | 132 1962 LANCET 2(7247):151-& KAJII T THALIDOMIDE AND CONGENITAL DEFORMITIES | 5 | 10 |
| 1912 | 0 | 0 | 133 1962 LANCET 2(7248):195-& FRANKLIN AW; RATTENBURY G; HERFORD M; NETTELL A THALIDOMIDE-DAMAGED INFANTS | 0 | 0 |
| 1913 | 2 | 2 | 134 1962 LANCET 2(7249):249-& KNAPP V; CHRISTIE GA; SELLER MJ THALIDOMIDE AND CONGENITAL ABNORMALITIES | 42 | 68 |
| 1914 | 0 | 0 | 135 1962 LANCET 2(7249):249-& DALDERUP LM THALIDOMIDE AND TEETH | 2 | 2 |
| 1915 | 0 | 0 | 136 1962 LANCET 2(7250):297-& JACOBS J THALIDOMIDE DAMAGED INFANTS | 0 | 0 |
| 1916 | 2 | 3 | 137 1962 LANCET 2(7250):298-& GLICK EN; GIROUD A; TUCHMANNDUPLESSIS H; MERCIERPAROT L THALIDOMIDE AND CONGENITAL ABNORMALITIES | 0 | 62 |
| 1917 | 0 | 1 | 138 1962 LANCET 2(7250):306-& [Anon] THALIDOMIDE BABIES | 0 | 0 |
| 1918 | 4 | 10 | 139 1962 LANCET 2(7251):336-& [Anon] THALIDOMIDE .2. | 0 | 0 |
| 1919 | 0 | 0 | 140 1962 LANCET 2(7251):349-& WIGGLESWORTH R THALIDOMIDE-DAMAGED INFANTS | 2 | 2 |
| 1920 | 0 | 0 | 141 1962 LANCET 2(7252):400-& TOMS DA; APPLEBEY M; HUNTER TAA; WOOLLAM DHM; ASHLEY DJB THALIDOMIDE AND CONGENITAL ABNORMALITIES | 4 | 6 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1921 | 0 | 2 | 142 1962 LANCET 2(7253):452-& DIJKHUIS HJ; JONGE GAD; BEKKER BV; VANCREVELD S; MONCHY GD; GREENE R; HAGENBEE.JH THALIDOMIDE AND CONGENITAL ABNORMALITIES | 0 | 0 |
| 1922 | 0 | 0 | 143 1962 LANCET 2(7253):452-& TRUETA J; AGERHOLM M THALIDOMIDE-DAMAGED INFANTS | 1 | 1 |
| 1923 | 1 | 34 | 144 1962 LANCET 2(7256):599-& MILLEN JW THALIDOMIDE AND LIMB DEFORMITIES | 0 | 16 |
| 1924 | 0 | 1 | 145 1962 LANCET 2(7258):724-& FELISATI D; KNAPP VI THALIDOMIDE AND CONGENITAL ABNORMALITIES | 28 | 47 |
| 1925 | 1 | 7 | 146 1962 LANCET 2(7260):812-& ROATH S; ISRAELS MCG; ELVES MW EFFECT OF THALIDOMIDE ON LEUCOCYTE CULTURES | 22 | 30 |
| 1926 | 0 | 0 | 147 1962 LANCET 2(7260):836-& OWEN R; SMITH A COR TRILOCULARE AND THALIDOMIDE | 3 | 5 |
| 1927 | 1 | 1 | 148 1962 LANCET 2(7260):836-& HUGHES DT; PLAYFAIR JH; HOPPER PK; DELHANTY JD; CHITHAM RG CHROMOSOMES OF THALIDOMIDE-DEFORMED FOETUSES | 6 | 9 |
| 1928 | 1 | 7 | 149 1962 LANCET 2(7260):836-& KEMPER FH THALIDOMIDE AND CONGENITAL ABNORMALITIES | 25 | 36 |
| 1929 | 0 | 0 | 150 1962 LANCET 2(7262):931-& [Anon] CONGENITAL ABNORMALITIES DUE TO THALIDOMIDE | 1 | 0 |
| 1930 | 0 | 1 | 151 1962 LANCET 2(7262):937-& CAMERON JM; CHRISTIE GA THALIDOMIDE AND CONGENITAL ABNORMALITIES | 2 | 6 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1931 | 0 | 0 | 152 1962 LANCET 2(7263):986-& [Anon] CONGENITAL ABNORMALITIES DUE TO THALIDOMIDE | 1 | 0 |
| 1932 | 5 | 35 | 153 1962 LANCET 2(7265):1095-& [Anon] THALIDOMIDE AND AFTER | 0 | 0 |
| 1933 | 0 | 0 | 154 1962 LANCET 2(7265):1116-& KING CTG; KENDRICK FJ TERATOGENIC EFFECTS OF THALIDOMIDE IN SPRAGUE DAWLEY RAT | 22 | 48 |
| 1934 | 0 | 0 | 155 1962 LANCET 2(7266):1162-& TRUETA J CARE OF THALIDOMIDE BABIES - EXPERIENCE IN GERMANY | 0 | 0 |
| 1935 | 0 | 0 | 156 1962 LANCET 2(7269):1332-& LUERS H FAILURE OF MUTAGENIC ACTION OF THALIDOMIDE IN DROSOPHILA | 5 | 8 |
| 1936 | 0 | 4 | 225 1963 LANCET 1(727):174-& PETERSEN CE; WIEDEMANN HR THALIDOMIDE AND FOETAL ABNORMALITIES | 2 | 4 |
| 1937 | 3 | 13 | 226 1963 LANCET 1(727):249-& ROATH S; ELVES MW; ISRAELS MCG EFFECTS OF THALIDOMIDE AND ITS DERIVATIVES ON HUMAN LEUCOCYTES CULTURED IN VITRO | 47 | 66 |
| 1938 | 0 | 0 | 227 1963 LANCET 1(727):501-& KAJII T; SHINOHARA M THALIDOMIDE IN JAPAN | 1 | 5 |
| 1939 | 0 | 0 | 228 1963 LANCET 1(727):501-& SWEETNAM WP THALIDOMIDE AND NEED TO LABEL DRUGS | 0 | 0 |
| 1940 | 2 | 3 | 229 1963 LANCET 1(728):552-& YANG T; LIANG H THALIDOMIDE AND CONGENITAL ABNORMALITIES | 0 | 8 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1941 | 2 | 2 | 230 1963 LANCET 1(728):552-& BOYLEN JB; JOHNSON WJ; HORNE HH TERATOGENIC EFFECTS OF THALIDOMIDE AND RELATED SUBSTANCES | 20 | 33 |
| 1942 | 0 | 0 | 231 1963 LANCET 1(728):553-& SAWISTOWSKA M THALIDOMIDE AND NEED TO LABEL DRUGS | 0 | 0 |
| 1943 | 0 | 1 | 232 1963 LANCET 1(728):723-& WILLIAMS RT TERATOGENIC EFFECTS OF THALIDOMIDE AND RELATED SUBSTANCES | 18 | 39 |
| 1944 | 3 | 14 | 233 1963 LANCET 1(728):724-& ROSENDAL T THALIDOMIDE AND APLASIA-HYPOPLASIA OF OTIC LABYRINTH | 0 | 7 |
| 1945 | 0 | 5 | 234 1963 LANCET 1(728):725-& VILLA L; ERIDANI S CYTOLOGICAL EFFECTS OF THALIDOMIDE | 4 | 7 |
| 1946 | 0 | 0 | 235 1963 LANCET 1(728):772-& EHMANN B TERATOGENIC EFFECTS OF THALIDOMIDE | 7 | 13 |
| 1947 | 0 | 0 | 236 1963 LANCET 1(728):959-& FRANKLIN AW PHYSICALLY HANDICAPPED BABIES - SOME THALIDOMIDE LESSONS | 0 | 8 |
| 1948 | 1 | 5 | 237 1963 LANCET 1(728):1003-& PLAYFAIR JH; DAVIES AJS; LEUCHARS E EFFECT OF THALIDOMIDE ON SKIN-GRAFT SURVIVAL | 0 | 18 |
| 1949 | 5 | 20 | 238 1963 LANCET 1(729):1095-& SMITHELLS RW; LECK I INCIDENCE OF LIMB AND EAR DEFECTS SINCE WITHDRAWAL OF THALIDOMIDE | 2 | 24 |
| 1950 | 4 | 10 | 239 1963 LANCET 1(729):1374-& NARROD SA; KING CTG METABOLIC STUDIES WITH THALIDOMIDE | 4 | 9 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1951 | 0 | 1 | 240 1963 LANCET 1(729):1375-& DIJKHUIS HJ; VANDUYNE WM; BEKKER BV THALIDOMIDE AND CONGENTIAL ABNORMALITIES | 0 | 0 |
| 1952 | 1 | 6 | 241 1963 LANCET 2(729):151-& KAJII T; GOTO M CLEFT LIP AND PALATE AFTER THALIDOMIDE | 1 | 2 |
| 1953 | 3 | 8 | 242 1963 LANCET 2(730):405-& LINDAHLKIESSLIN.K; BOOK JA EFFECTS OF THALIDOMIDE ON HUMAN LEUCOCYTE CULTURES | 16 | 23 |
| 1954 | 0 | 7 | 243 1963 LANCET 2(731):889-& KAJII T; AKICHIKA M; DOHMEN S; SHINOHARA M; KIKUCHI K THALIDOMIDE AND UMBILICAL ARTERY | 1 | 11 |
| 1955 | 4 | 12 | 244 1963 LANCET 2(731):1068-& MILLER ZB INHIBITION OF TISSUE-CULTURE GROWTH BY A SOLUBLE THALIDOMIDE DERIVATIVE | 5 | 9 |
| 1956 | 4 | 14 | 288 1964 LANCET 1(733):724-& FELISATI D TERATOGENIC ACTION OF THALIDOMIDE | 6 | 11 |
| 1957 | 0 | 2 | 289 1964 LANCET 2(735):574-& [Anon] THALIDOMIDE | 0 | 0 |
| 1958 | 0 | 0 | 341 1965 LANCET 2(7417):855-& MCBRIDE WG THALIDOMIDE | 0 | 0 |
| 1959 | 5 | 19 | 342 1965 LANCET 2(7421):1059-& [Anon] ANOTHER CHANCE FOR THALIDOMIDE | 7 | 0 |
| 1960 | 0 | 1 | 343 1965 LANCET 2(7421):1074-& SPEIRS AL THALIDOMIDE | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1961 | 3 | 5 | 389 1966 LANCET 1(7428):92-& BOHM R; NITSCH K ANOTHER CHANCE FOR THALIDOMIDE | 1 | 1 |
| 1962 | 2 | 4 | 390 1966 LANCET 1(7430):207-& FLOERSHE.GL ANOTHER CHANCE FOR THALIDOMIDE | 0 | 11 |
| 1963 | 2 | 2 | 391 1966 LANCET 1(7434):432-& HELLMANN K ANOTHER CHANCE FOR THALIDOMIDE | 0 | 0 |
| 1964 | 2 | 3 | 392 1966 LANCET 1(7438):665-& MAINARDI PC; BORRONE C; TAMBUSSI AM ANOTHER CHANCE FOR THALIDOMIDE | 0 | 0 |
| 1965 | 2 | 2 | 393 1966 LANCET 1(7442):882-& MOUZAS GL ANOTHER CHANCE FOR THALIDOMIDE | 1 | 2 |
| 1966 | 2 | 14 | 394 1966 LANCET 1(7444):981-& VLADUTIU A ANOTHER CHANCE FOR THALIDOMIDE | 2 | 2 |
| 1967 | 3 | 10 | 395 1966 LANCET 1(7447):1134-& TURK JL; HELLMANN K; DUKE DI EFFECT OF THALIDOMIDE ON IMMUNOLOGICAL RESPONSE IN LOCAL LYMPH NODES AFTER A SKIN HOMOGRAFT | 28 | 32 |
| 1968 | 0 | 3 | 396 1966 LANCET 1(7447):1134-& CANT JS MINOR OCULAR ABNORMALITIES ASSOCIATED WITH THALIDOMIDE | 2 | 4 |
| 1969 | 7 | 23 | 397 1966 LANCET 1(7447):1136-& HELLMANN K IMMUNOSUPPRESSION BY THALIDOMIDE - IMPLICATIONS FOR TERATOLOGY | 14 | 20 |
| 1970 | 10 | 19 | 398 1966 LANCET 1(7449):1240-& BORE PJ; SCOTHORN.RJ EFFECT OF THALIDOMIDE ON SURVIVAL OF SKIN HOMOGRAFTS IN RABBITS | 16 | 18 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1971 | 1 | 8 | 399 1966 LANCET 1(7449):1263-& EVERED DF ANOTHER CHANCE FOR THALIDOMIDE | 0 | 0 |
| 1972 | 0 | 0 | 400 1966 LANCET 1(7450):1330-& GEBHARDT DO IMMUNOSUPPRESSION BY THALIDOMIDE | 0 | 0 |
| 1973 | 8 | 20 | 401 1966 LANCET 1(7451):1373-& CHARD T; HELLMANN K IMMUNOSUPPRESSION BY THALIDOMIDE | 3 | 3 |
| 1974 | 8 | 13 | 437 1967 LANCET 1(7489):569-& DUKOR P; DIETRICH FM IMMUNOSUPRESSION BY THALIDOMIDE | 10 | 13 |
| 1975 | 0 | 16 | 438 1967 LANCET 2(7509):242-& STAINSBY GD; QUIBELL EP PERTHES-LIKE CHANGES IN HIPS OF CHILDREN WITH THALIDOMIDE DEFORMITIES | 0 | 2 |
| 1976 | 1 | 3 | 439 1967 LANCET 2(7515):562-& LENZ W PERTHES-LIKE CHANGES IN THALIDOMIDE CHILDREN | 0 | 0 |
| 1977 | 0 | 0 | 469 1968 LANCET 1(7539):428-& HILL MM SETTLEMENT OF CLAIMS OF THALIDOMIDE FAMILIES | 0 | 0 |
| 1978 | 4 | 16 | 486 1969 LANCET 1(7597):713-& [Anon] THALIDOMIDE NEUROPATHY | 5 | 0 |
| 1979 | 0 | 1 | 487 1969 LANCET 2(7615):331-& WHICHER H DAMAGES AWARDED FOR THALIDOMIDE CHILDREN | 0 | 0 |
| 1980 | 2 | 13 | 507 1970 LANCET 1(7641):275-& PEMBREY ME; CLARKE CA NORMAL CHILD AFTER MATERNAL THALIDOMIDE INGESTION IN CRITICAL PERIOD OF PREGNANCY | 4 | 8 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1981 | 2 | 2 | 573 1973 LANCET 2(7824):324-325 LEVY L; FASAL P; LEVAN NE; FREEDMAN RI TREATMENT OF ERYTHEMA-NODOSUM LEPROSUM WITH THALIDOMIDE | 8 | 10 |
| 1982 | 6 | 21 | 574 1973 LANCET 2(7828):567-568 CRAWFORD CL TREATMENT OF ERYTHEMA-NODOSUM LEPROSUM WITH THALIDOMIDE | 5 | 5 |
| 1983 | 0 | 7 | 575 1973 LANCET 2(7835):966-966 SWIFT TR THALIDOMIDE IN ERYTHEMA-NODOSUM LEPROSUM | 0 | 0 |
| 1984 | 3 | 12 | 576 1973 LANCET 2(7837):1058-1061 MCCREDIE J THALIDOMIDE AND CONGENITAL CHARCOTS JOINTS | 8 | 49 |
| 1985 | 0 | 8 | 577 1973 LANCET 2(7839):1201-1202 CRAWFORD CL THALIDOMIDE IN ERYTHEMA-NODOSUM LEPROSUM | 0 | 2 |
| 1986 | 1 | 12 | 597 1974 LANCET 1(7849):165-166 SABIN TD THALIDOMIDE NEUROPATHY AND LEPROUS NEURITIS | 0 | 1 |
| 1987 | 1 | 3 | 598 1974 LANCET 1(7866):1111-1111 MCCREDIE J; MCLEOD JG THALIDOMIDE AND EMBRYONIC NEUROPATHY | 5 | 11 |
| 1988 | 5 | 9 | 614 1975 LANCET 1(7906):560-560 [Anon] POSTSCRIPT TO THALIDOMIDE | 0 | 0 |
| 1989 | 0 | 0 | 615 1975 LANCET 1(7913):985-985 LESSER E POSTSCRIPT TO THALIDOMIDE | 0 | 0 |
| 1990 | 2 | 18 | 625 1976 LANCET 1(7960):635-637 GARDNER E; ORAHILLY R NEURAL CREST, LIMB DEVELOPMENT, AND THALIDOMIDE EMBRYOPATHY | 1 | 14 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 1991 | 0 | 0 | 626 1976 LANCET 2(7989):794-794 HOFFMANN W; GROSPIETSCH G; KUHN W THALIDOMIDE AND FEMALE GENITAL MALFORMATIONS | 0 | 4 |
| 1992 | 1 | 4 | 651 1977 LANCET 1(8005):251-251 ERAVELLY J; WATERS MFR THALIDOMIDE IN WEBER-CHRISTIAN DISEASE | 32 | 37 |
| 1993 | 1 | 2 | 652 1977 LANCET 2(8034):405-405 TEPPO L; SAXEN E; TERVO T; PARTIO E; VONBONSDORFF H; SALMELA J; AVIKAINEN V; ISOMAKI M; KREES R THALIDOMIDE-TYPE MALFORMATIONS AND SUBSEQUENT OSTEOSARCOMA | 2 | 2 |
| 1994 | 1 | 3 | 674 1978 LANCET 1(8068):826-826 BREMNER DN; MOONEY G AGENESIS OF APPENDIX - FURTHER THALIDOMIDE ANOMALY | 0 | 5 |
| 1995 | 1 | 2 | 675 1978 LANCET 1(8072):1042-1042 SMITHELLS RW THALIDOMIDE, ABSENT APPENDIX, AND SWEATING | 2 | 4 |
| 1996 | 3 | 7 | 676 1978 LANCET 1(8078):1362-1362 MCBRIDE WG TERATOGENIC ACTION OF THALIDOMIDE | 1 | 1 |
| 1997 | 0 | 1 | 677 1978 LANCET 2(8085):385-385 [Anon] THALIDOMIDE | 0 | 0 |
| 1998 | 0 | 0 | 757 1981 LANCET 2(8242):368-368 MCBRIDE WG ANOTHER, LATE THALIDOMIDE ABNORMALITY | 1 | 1 |
| 1999 | 1 | 1 | 758 1981 LANCET 2(8245):510-511 [Anon] THALIDOMIDE - 20 YEARS ON | 0 | 0 |
| 2000 | 1 | 4 | 857 1984 LANCET 2(8394):98-99 NIELSEN H; BENNIKE T THALIDOMIDE ENHANCES DEFECTIVE MONOCYTE FUNCTION IN LEPROMATOUS LEPROSY | 6 | 8 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2001 | 0 | 5 | 858 1984 LANCET 2(8396):205-206 [Anon] DEBENDOX IS NOT THALIDOMIDE | 0 | 0 |
| 2002 | 7 | 11 | 859 1984 LANCET 2(8417):1424-1426 JENKINS JS; POWELL RJ; ALLEN BR; LITTLEWOOD SM; MAURICE PDL; SMITH NJ THALIDOMIDE IN SEVERE OROGENITAL ULCERATION | 25 | 35 |
| 2003 | 1 | 10 | 897 1985 LANCET 1(8423):288-289 LEHNER T; SULLIVAN FM THALIDOMIDE, OROGENITAL ULCERS, AND THE RISK OF TERATOGENESIS | 1 | 3 |
| 2004 | 1 | 2 | 898 1985 LANCET 1(8427):511-511 JENKINS S; POWELL RJ; ALLEN BR; LITTLEWOOD S; MAURICE PD; SMITH NJ THALIDOMIDE, OROGENITAL ULCERS, AND RISK OF TERATOGENICITY | 2 | 3 |
| 2005 | 15 | 15 | 899 1985 LANCET 2(8446):80-81 [Anon] THALIDOMIDE IN DERMATOLOGY AND LEPROSY | 7 | 0 |
| 2006 | 5 | 8 | 900 1985 LANCET 2(8450):331-331 CRAWFORD CL THALIDOMIDE AND LEPROSY | 1 | 1 |
| 2007 | 4 | 4 | 970 1988 LANCET 1(8577):117-117 LIM SH; MCWHANNELL A; VORA AJ; BOUGHTON BJ SUCCESSFUL TREATMENT WITH THALIDOMIDE OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER BONE-MARROW TRANSPLANTATION | 32 | 35 |
| 2008 | 3 | 5 | 971 1988 LANCET 1(8581):359-359 SAURAT JH; CAMENZIND M; HELG C; CHAPUIS B THALIDOMIDE FOR GRAFT-VERSUS-HOST DISEASE AFTER BONE-MARROW TRANSPLANTATION | 26 | 31 |
| 2009 | 3 | 6 | 972 1988 LANCET 1(8589):827-827 VOGELSANG GB; SANTOS GW; COLVIN OM; CHEN TL THALIDOMIDE FOR GRAFT-VERSUS-HOST DISEASE | 12 | 25 |
| 2010 | 2 | 3 | 973 1988 LANCET 2(8610):568-568 RINGDEN O; ASCHAN J; WESTERBERG L THALIDOMIDE FOR SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE | 8 | 9 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2011 | 2 | 2 | 974 1988 LANCET 2(8620):1135-1135 MCCARTHY DM; KANFER E; TAYLOR J; BARRETT AJ THALIDOMIDE FOR GRAFT-VERSUS-HOST DISEASE | 19 | 21 |
| 2012 | 3 | 3 | 975 1988 LANCET 2(8623):1317-1317 HENEY D; LEWIS IJ; BAILEY CC THALIDOMIDE FOR CHRONIC GRAFT-VERSUS-HOST DISEASE IN CHILDREN | 9 | 14 |
| 2013 | 3 | 3 | 1021 1990 LANCET 335(8701):1343-1343 GORIN I; VILETTE B; GEHANNO P; ESCANDE JP THALIDOMIDE IN HYPERALGIC PHARYNGEAL ULCERATION OF AIDS | 21 | 31 |
| 2014 | 1 | 4 | 1022 1990 LANCET 335(8705):1591-1591 YOULE M; HAWKINS D; GAZZARD B THALIDOMIDE IN HYPERALGIC PHARYNGEAL ULCERATION OF AIDS | 9 | 11 |
| 2015 | 1 | 4 | 1047 1991 LANCET 337(8738):436-437 WILLIAMS I; WELLER IVD; MALIN A; ANDERSON J; WATERS MFR THALIDOMIDE HYPERSENSITIVITY IN AIDS | 26 | 34 |
| 2016 | 3 | 5 | 1064 1992 LANCET 339(8789):365-365 WINTER W; FRANKUS E THALIDOMIDE ENANTIOMERS | 12 | 18 |
| 2017 | 5 | 7 | 1065 1992 LANCET 339(8792):549-550 BESSIS D; GUILLOT B; MONPOINT S; DANDURAND M; GUILHOU JJ THALIDOMIDE FOR SYSTEMIC LUPUS-ERYTHEMATOSUS | 27 | 31 |
| 2018 | 0 | 1 | 1066 1992 LANCET 339(8800):1057-1057 HAWKINS DF THALIDOMIDE FOR SYSTEMIC LUPUS-ERYTHEMATOSUS | 7 | 8 |
| 2019 | 5 | 6 | 1067 1992 LANCET 339(8805):1362-1362 CARMICHAEL AJ; KNIGHT A THALIDOMIDE - A RESTRICTED ROLE | 3 | 5 |
| 2020 | 2 | 2 | 1068 1992 LANCET 339(8805):1362-1362 HIGGINS SP; BRADBEER CS THALIDOMIDE - A RESTRICTED ROLE | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2021 | 5 | 12 | 1148 1994 LANCET 343(8895):432-433 JAKEMAN P; SMITH WCS THALIDOMIDE IN LEPROSY REACTION | 8 | 14 |
| 2022 | 0 | 1 | 1149 1994 LANCET 343(8900):795-796 CUTLER J THALIDOMIDE REVISITED | 4 | 5 |
| 2023 | 3 | 5 | 1150 1994 LANCET 343(8904):1041-1041 JONES GRN THALIDOMIDE - 35 YEARS ON AND STILL DEFORMING | 4 | 5 |
| 2024 | 3 | 5 | 1151 1994 LANCET 344(8916):196-197 TEIXEIRA F; HOJYO MT; ARENAS R; VEGA ME; CORTES R; ORTIZ A; DOMINGUEZ L THALIDOMIDE - CAN IT CONTINUE TO BE USED | 4 | 4 |
| 2025 | 0 | 0 | 1209 1995 LANCET 346(8985):1289-1289 THOMPSON C THALIDOMIDE EFFECTIVE FOR AIDS-RELATED ORAL ULCERS | 5 | 10 |
| 2026 | 2 | 5 | 1283 1996 LANCET 347(9006):974-974 Verberkmoes A; Boer K; Wertheim PME; Bronkhorst CM; Lange JMA Thalidomide for genital ulcer in HIV-positive woman | 4 | 9 |
| 2027 | 0 | 0 | 1284 1996 LANCET 348(9038):1370-1370 Barnett AA FDA encourages firms to test thalidomide | 0 | 0 |
| 2028 | 0 | 0 | 1365 1997 LANCET 349(9045):111-111 Barnett AA Company applies to market thalidomide in USA | 0 | 0 |
| 2029 | 0 | 1 | 1366 1997 LANCET 350(9081):873-873 Ault A Thalidomide comes close to US approval | 1 | 1 |
| 2030 | 2 | 5 | 1367 1997 LANCET 350(9089):1445-1446 Wettstein AR; Meagher AP Thalidomide in Crohn's disease | 34 | 52 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2031 | 1 | 30 | 1457 1998 LANCET 351(9110):1197-1199 Dally A Thalidomide: was the tragedy preventable? | 6 | 16 |
| 2032 | 2 | 5 | 1458 1998 LANCET 351(9115):1591-1591 Smithells D Was the thalidomide tragedy preventable? | 0 | 0 |
| 2033 | 1 | 5 | 1459 1998 LANCET 351(9115):1591-1591 Critchley EMR Was the thalidomide tragedy preventable? | 0 | 0 |
| 2034 | 0 | 0 | 1460 1998 LANCET 352(9124):298-298 Ault A Thalidomide makes a return to US health care | 0 | 0 |
| 2035 | 5 | 5 | 1461 1998 LANCET 352(9127):544-545 Stambe C; Wicks IP TNF alpha and response of treatment-resistant adult-onset Still's disease to thalidomide | 10 | 24 |
| 2036 | 8 | 28 | 1462 1998 LANCET 352(9140):1586-1589 Wolkenstein P; Latarjet J; Roujeau JC; Duguet C; Boudeau S; Vaillant L; Maignan M; Schuhmacher MH; Milpied B; Pilorget A; Bocquet H; Brun-Buisson C; Revuz J Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis | 39 | 78 |
| 2037 | 4 | 5 | 1573 1999 LANCET 353(9149):324-324 Klausner JD; Kaplan G; Haslett PAJ Thalidomide in toxic epidermal necrolysis | 7 | 8 |
| 2038 | 1 | 2 | 1574 1999 LANCET 353(9149):324-324 Levy R Thalidomide in toxic epidermal necrolysis | 1 | 2 |
| 2039 | 1 | 1 | 1575 1999 LANCET 353(9163):1503-1503 Moore P Thalidomide's teratogenic mechanism starts to yield to study | 0 | 0 |
| 2040 | 0 | 0 | 1576 1999 LANCET 354(9182):925-925 Larkin M Low-dose thalidomide seems to be effective in multiple myeloma | 9 | 14 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2041 | 0 | 0 | 1577 1999 LANCET 354(9191):1705-1705 Larkin M Thalidomide continues to look promising as an anticancer agent | 1 | 1 |
| 2042 | 2 | 5 | 1753 2000 LANCET 356(9229):566-567 Govindarajan R; Heaton KM; Broadwater R; Zeitlin A; Lang NP; Hauer-Jensen M Effect of thalidomide on gastrointestinal toxic effects of irinotecan | 20 | 27 |
| 2043 | 3 | 5 | 2653 2004 LANCET 363(9403):169-169 McBride W Health of thalidomide victims and their progeny | 0 | 0 |
| 2044 | 132 | 159 | 2654 2004 LANCET 363(9423):1802-1811 Franks ME; Macpherson GR; Figg WD Thalidomide | 0 | 0 |
| 2045 | 2 | 5 | 2655 2004 LANCET 363(9424):1911-1911 Crawford CL Does thalidomide have a role in leprosy? | 0 | 0 |
| 2046 | 0 | 5 | 1973 2001 LANCET ONCOLOGY 2(10):634-635 Hwu WJ; Raizer J; Panageas KS; Lis E Treatment of metastatic melanoma in the brain with temozolomide and thalidomide | 3 | 5 |
| 2047 | 0 | 0 | 2252 2002 LANCET ONCOLOGY 3(12):711-711 Lindsey H Thalidomide plus dexamethasone for newly diagnosed myeloma | 0 | 0 |
| 2048 | 0 | 0 | 2508 2003 LANCET ONCOLOGY 4(2):70-70 Bonn D Thalidomide: no benefit in myelofibrosis with myeloid metaplasia | 0 | 0 |
| 2049 | 0 | 0 | 2509 2003 LANCET ONCOLOGY 4(12):713-713 Habeck M Australia approves thalidomide | 0 | 0 |
| 2050 | 0 | 344 1965 LEPROSY REVIEW 36:183-187 SHESKIN J Further observations with thalidomide in lepra reactions | 38 | 52 | |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2051 | 2 | 7 | 901 1985 LEPROSY REVIEW 56(1):35-39 GAD SM; SHANNON EJ; KROTOSKI WA; HASTINGS RC THALIDOMIDE INDUCES IMBALANCES IN LYMPHOCYTE-T SUB-POPULATIONS IN THE CIRCULATING BLOOD OF HEALTHY-MALES | 50 | 65 |
| 2052 | 6 | 13 | 902 1985 LEPROSY REVIEW 56(4):297-301 SHANNON EJ; TRUMAN RW; CHRISTY SA; BROWN LM; VADIEE R; HASTINGS RC EFFECT OF THALIDOMIDE ON INDUCTION OF ANTIBODY-SYNTHESIS IN MICE TO THE T-INDEPENDENT ANTIGEN, DNP-FICOLL | 5 | 6 |
| 2053 | 0 | 0 | 926 1986 LEPROSY REVIEW 57(1):76-77 LORETTI A; BARCHI E SUPPLIES OF THALIDOMIDE FOR USE IN LEPROSY | 1 | 1 |
| 2054 | 1 | 1 | 927 1986 LEPROSY REVIEW 57(3):273-273 NEELAMKAVIL P SUPPLIES OF THALIDOMIDE FOR USE IN LEPROSY | 1 | 2 |
| 2055 | 0 | 0 | 976 1988 LEPROSY REVIEW 59(2):184-185 BOURDILLON C THALIDOMIDE IN ERYTHEMA-NODOSUM LEPROSUM (ENL) | 0 | 0 |
| 2056 | 10 | 16 | 1368 1997 LEPROSY REVIEW 68(1):61-66 Powell RJ; GardnerMedwin JMM Guideline for the clinical use and dispensing of thalidomide (Reprinted from the Postgraduate Medical Journal, vol 70, pg 901-904, 1994) | 1 | 3 |
| 2057 | 16 | 19 | 1754 2000 LEPROSY REVIEW 71:S117-S120 Kaplan G Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions | 1 | 2 |
| 2058 | 0 | 0 | 1755 2000 LEPROSY REVIEW 71:S120-S120 Ottenhoff THM; Kaplan G; Gillis TP Potential of thalidomide and thalidomide analogues as immunomodulatory drugs in leprosy and leprosy reactions - Discussion | 0 | 0 |
| 2059 | 9 | 20 | 2510 2003 LEPROSY REVIEW 74(3):206-214 Tadesse A; Taye E; Sandoval F; Shannow EJ Thalidomide does not modify the ability of cells in leprosy patients to incorporate [H-3]-thymidine when incubated with M-leprae antigens | 0 | 0 |
| 2060 | 3 | 20 | 2511 2003 LEPROSY REVIEW 74(3):286-288 Pannikar V The return of thalidomide: new uses and renewed concerns | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2061 | 7 | 32 | 2512 2003 LEPROSY REVIEW 74(3):288-290 Pereira GFM On thalidomide and VMO policies | 0 | 0 |
| 2062 | 6 | 28 | 2513 2003 LEPROSY REVIEW 74(3):290-294 Lockwood D; Bryceson A The return of thalidomide: new uses and renewed concerns - reply | 0 | 2 |
| 2063 | 0 | 0 | 2514 2003 LEPROSY REVIEW 74(3):294-295 Naafs B The return of thalidomide: new uses and renewed concerns - reply | 0 | 1 |
| 2064 | 0 | 0 | 1974 2001 LEUKEMIA 15(3):491-491 Barlogie D; Spencer T; Tricot G; Zeldis J; Munshi N; Zangari M; Badros A; Toor A; Shaughnessy J; Morris C; Desikan R Long term follow up of 169 patients receiving a phase II trial of single agent thalidomide for advanced and refractory multiple myeloma (MM). | 0 | 0 |
| 2065 | 10 | 19 | 1975 2001 LEUKEMIA 15(8):1274-1276 Rajkumar SV; Dispenzieri A; Fonseca R; Lacy MQ; Geyer S; Lust JA; Kyle RA; Greipp PR; Gertz MA; Witzig TE Thalidomide for previously untreated indolent or smoldering multiple myeloma | 28 | 43 |
| 2066 | 7 | 22 | 2253 2002 LEUKEMIA 16(1):1-6 Strupp C; Germing U; Aivado M; Misgeld E; Haas R; Gattermann N Thalidomide for the treatment of patients with myelodysplastic syndromes | 14 | 25 |
| 2067 | 11 | 38 | 2254 2002 LEUKEMIA 16(9):1609-1614 Piccaluga PP; Visani G; Pileri SA; Ascani S; Grafone T; Isidori A; Malagola M; Finelli C; Martinelli G; Ricci P; Baccarani M; Tura S Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study | 7 | 12 |
| 2068 | 8 | 17 | 2515 2003 LEUKEMIA 17(1):41-44 Lentzsch S; LeBlanc R; Podar K; Davies F; Lin B; Hideshima T; Catley L; Stirling DI; Anderson KC Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo | 7 | 16 |
| 2069 | 12 | 32 | 2516 2003 LEUKEMIA 17(4):775-779 Rajkumar SV; Gertz MA; Lacy MQ; Dispenzieri A; Fonseca R; Geyer SM; Iturria N; Kumar S; Lust JA; Kyle RA; Greipp PR; Witzig TE Thalidomide as initial therapy for early-stage myeloma | 11 | 18 |
| 2070 | 5 | 8 | 2517 2003 LEUKEMIA 17(6):1200-1202 Strupp C; Hildebrandt B; Germing U; Haas R; Gattermann N Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome | 0 | 1 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2071 | 5 | 8 | 2518 2003 LEUKEMIA 17(8):1669-1670 Visani G; Mele A; Malagola M; Isidori A; Finelli C; Piccaluga PP Sequential combination of thalidomide and erythropoietin determines transfusion independence and disease control in idiopathic myelofibrosis previously insensitive to both drugs used as single agents | 1 | 1 |
| 2072 | 10 | 11 | 2519 2003 LEUKEMIA 17(9):1914-1915 Damaj G; Lefrere F; Delarue R; Varet B; Furman R; Hermine O Thalidomide therapy induces response in relapsed mantle cell lymphoma | 0 | 0 |
| 2073 | 3 | 8 | 2520 2003 LEUKEMIA 17(10):2056-2057 Dalle JH; Leblond P; Decouvelaere A; Yakoub-Agha I; Preudhomme C; Nelken B; Mazingue F Efficacy of thalidomide in a child with histiocytic sarcoma following allogeneic bone marrow tranplantation for T-ALL | 0 | 0 |
| 2074 | 3 | 6 | 2521 2003 LEUKEMIA 17(11):2237-2238 Mehta P; Hussein M Thalidomide as anti-inflammatory therapy for multiple myeloma | 0 | 0 |
| 2075 | 2 | 6 | 2522 2003 LEUKEMIA 17(11):2238-2238 Rajkumar SV; Witzig TE Thalidomide as anti-inflammatory therapy for multiple myeloma - Reply | 0 | 0 |
| 2076 | 11 | 40 | 2656 2004 LEUKEMIA 18(3):624-627 Kumar S; Witzig TE; Dispenzieri A; Lacy MQ; Wellik LE; Fonseca R; Lust JA; Gertz MA; Kyle RA; Greipp PR; Rajkumar SV Effect of thalidomide therapy on bone marrow angiogenesis in multiple myeloma | 1 | 1 |
| 2077 | 27 | 54 | 2657 2004 LEUKEMIA 18(4):856-863 Garcia-Sanz R; Gonzalez-Porras JR; Hernandez JM; Polo-Zarzuela M; Sureda A; Barrenetxea C; Palomera L; Lopez R; Grande-Garcia C; Alegre A; Vargas-Pabon M; Gutierrez ON; Rodriguez JA; San Miguel JF The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma | 0 | 1 |
| 2078 | 8 | 17 | 1976 2001 LEUKEMIA & LYMPHOMA 42(4):683-+ Avigdor A; Raanani P; Levi I; Hardan I; Ben-Bassat I Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma | 8 | 9 |
| 2079 | 5 | 24 | 2255 2002 LEUKEMIA & LYMPHOMA 43(1):133-137 Strupp C; Aivado M; Germing U; Gattermann N; Haas R Angioimmunoblastic lymphadenopathy (AILD) may respond to thalidomide treatment: Two case reports | 1 | 4 |
| 2080 | 7 | 8 | 2256 2002 LEUKEMIA & LYMPHOMA 43(2):351-354 Johnston RE; Abdalla SH Thalidomide in low doses is effective for the treatment of resistant or relapsed multiple myeloma and for plasma cell leukaemia | 7 | 9 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2081 | 4 | 26 | 2257 2002 LEUKEMIA & LYMPHOMA 43(2):401-406 Dmoszynska A; Bojarska-Junak A; Domanski D; Rolinski J; Hus M; Soroka-Wojtaszko M Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma | 2 | 6 |
| 2082 | 5 | 23 | 2258 2002 LEUKEMIA & LYMPHOMA 43(6):1267-1271 Badros A; Morris C; Zangari M; Barlogie B; Tricot G Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia | 3 | 3 |
| 2083 | 7 | 29 | 2259 2002 LEUKEMIA & LYMPHOMA 43(9):1777-1782 Coleman M; Leonard J; Lyons L; Pekle K; Nahum K; Pearse R; Niesvizky R; Michaeli J BLYD (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia | 4 | 6 |
| 2084 | 11 | 20 | 2260 2002 LEUKEMIA & LYMPHOMA 43(12):2301-2307 Giovanni B; Michelle E; Letizia C; Filippo B; Paolo PP; Giuseppe V; Monia M; Gabriele P; Francesca Z; Ayalew T Thalidomide in myelofibrosis with myeloid metaplasia: A pooled-analysis of individual patient data from five studies | 0 | 0 |
| 2085 | 13 | 57 | 2523 2003 LEUKEMIA & LYMPHOMA 44(2):291-298 Ribas C; Colleoni GWB Advances in the treatment of multiple myeloma: The role of thalidomide | 0 | 1 |
| 2086 | 12 | 13 | 2524 2003 LEUKEMIA & LYMPHOMA 44(6):989-991 Abdalla SH; Mahmoud S Thalidomide in relapsed or refractory multiple myeloma: How much and for how long? | 1 | 1 |
| 2087 | 1 | 6 | 2525 2003 LEUKEMIA & LYMPHOMA 44(6):1081-1082 Andretta C; Catalano L; Pace L; Fonti R; Annunziata G; Rotoli B 99mTc-sestaMIBI scintigraphy in thalidomide-treated refractory or relapsed multiple myeloma patients | 0 | 1 |
| 2088 | 30 | 38 | 2526 2003 LEUKEMIA & LYMPHOMA 44(7):1141-1146 Flowers MED; Martin PJ Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease | 0 | 0 |
| 2089 | 12 | 17 | 2527 2003 LEUKEMIA & LYMPHOMA 44(7):1147-1149 Wechalekar AD; Chen CI; Sutton D; Reece D; Voralia M; Stewart AK Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma | 1 | 1 |
| 2090 | 19 | 36 | 2528 2003 LEUKEMIA & LYMPHOMA 44(9):1489-1493 Steins MB; Bieker R; Padro T; Kessler T; Kienast J; Berdel WE; Mesters RM Thalidomide for the treatment of acute myeloid leukemia | 0 | 0 |
| # | LCR | NCR | Nodes / Date / Journal / Authors | LCS | GCS |
| 2091 | 12 | 18 | 2529 2003 LEUKEMIA & LYMPHOMA 44(11):1943-1946 Kees M; Dimou G; Sillaber C; Drach J; Ackermann J; Lechner K; Gisslinger H Low dose thalidomide in patients with relapsed or refractory multiple myeloma | 0 | 0 |
| 2092 | 10 | 18 | 2658 2004 LEUKEMIA & LYMPHOMA 45(1):113-116 Anagnostopoulos A; Hamilos G; Zorzou MP; Grigoraki V; Anagnostou D; Dimopoulos MA Discordant response or progression in patients with myeloma treated with thalidomide-based regimens | 0 | 0 |
| 2093 | 4 | 13 | 2659 2004 LEUKEMIA & LYMPHOMA 45(1):179-181 Baird R; van Zyl-Smit RN; Iveson A; Duddy J; Rassam S Thalidomide is highly effective in a patient with meningeal acute myeloid leukaemia | 0 | 0 |
| 2094 | 14 | 20 | 2660 2004 LEUKEMIA & LYMPHOMA 45(4):735-738 Balleari E; Ghio R; Falcone A; Musto P Possible multiple myeloma dedifferentiation following thalidomide therapy: A report of four cases | 0 | 0 |
| 2095 | 7 | 12 | 2661 2004 LEUKEMIA & LYMPHOMA 45(8):1711-1712 Montagut C; Bosch F; Villela L; Rosinol L; Blade J Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide | 0 | 0 |
| 2096 | 20 | 38 | 1023 1990 LEUKEMIA RESEARCH 14(5):395-399 WOOD PMD; PROCTOR SJ THE POTENTIAL USE OF THALIDOMIDE IN THE THERAPY OF GRAFT-VERSUS-HOST DISEASE - A REVIEW OF CLINICAL AND LABORATORY INFORMATION | 17 | 26 |
| 2097 | 1 | 20 | 1048 1991 LEUKEMIA RESEARCH 15(2-3):129-136 HATFILL SJ; FESTER ED; DEBEER DP; BOHM L INDUCTION OF MORPHOLOGICAL-DIFFERENTIATION IN THE HUMAN LEUKEMIC-CELL LINE K562 BY EXPOSURE TO THALIDOMIDE METABOLITES | 17 | 20 |
| 2098 | 3 | 5 | 2261 2002 LEUKEMIA RESEARCH 26(10):965-966 Tsirigotis P; Venetis E; Rontogianni D; Dervenoulas J; Kontopidou F; Apostolidis P Thalidomide in the treatment of myelodysplastic syndrome with fibrosis | 2 | 2 |
| 2099 | 12 | 27 | 2530 2003 LEUKEMIA RESEARCH 27(10):909-914 Schey SA; Cavenagh J; Johnson R; Child JA; Oakervee H; Jones RW An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment | 0 | 1 |
| 2100 | 15 | 59 | 2662 2004 LEUKEMIA RESEARCH 28(4):325-332 Musto P Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives | 0 | 0 |
Page 7: 1 2 3 4 5 6 7 8 9
Generated by: HistCite(Vlad).
Version: 2004.09.22